Yes. Those were people that are ccr5 deficient. With the flu, mice that were cc5 deficient died more from the lung infection, but one group thought it was because without ccr5 receptor, ccl3, ccl4, and ccl5 interfered with other receptors that helped, ( but the science is not nailed down as to exactly why.) So there is a difference between people without ccr5 receptors and people taking leronlimab, which means taking leronlimab is not equal to ccr5 deficient and it could be very very helpful, but just saying they need proceed with caution because it is a complicated area where the research isn't certain (and has a possibility of doing more harm than good in some areas).